9 Facts About Menopause and Colorectal Cancer Risk That Every Woman Over 45 Should Know
This one blindsided me. Nobody mentioned the colon when I was reading everything I could find about perimenopause. It wasn't until a friend got her first colonoscopy referral at 45 and started asking questions that I went down this particular rabbit hole — and what I found made me wish someone had flagged it sooner.
Learn more about Rose →Estrogen actively protects the colon lining — and its loss matters
Estrogen receptors are found throughout the gastrointestinal tract, including the colon, where estrogen helps regulate cell turnover and suppress inflammatory signalling that can drive abnormal growth. When estrogen levels fall during perimenopause and menopause, that protective brake is loosened, allowing pre-cancerous changes to develop more readily. This is why colorectal cancer incidence in women rises sharply after menopause, catching up with — and eventually exceeding — rates seen in age-matched men.
Women's colorectal cancer risk trajectory is different from men's — and that affects screening logic
For most of their reproductive years, women have a lower incidence of colorectal cancer than men of the same age, likely due to the protective effect of cycling estrogen. After menopause, that gap closes and then reverses, with postmenopausal women facing risk levels that outpace their male peers in some age brackets. Standard screening guidelines that treat men and women identically at age 50 (or 45 in updated US guidance) do not always account for this hormonal inflection point.
Perimenopause — not just postmenopause — is when vigilance should begin
Because perimenopause can begin in the early-to-mid forties and involves significant estrogen fluctuation before levels permanently decline, the window of changing colon cancer risk starts earlier than many women expect. Adenomatous polyps — the precursors to most colorectal cancers — typically take 10 to 15 years to progress, meaning polyps developing during perimenopause may become clinically significant well before a woman reaches her sixties. Starting the conversation about baseline colonoscopy during perimenopause, rather than waiting for a definitive menopause date, makes biological sense.
Combined HRT (estrogen plus progestogen) is associated with meaningfully lower colorectal cancer rates
Large observational studies, including data from the Women's Health Initiative (WHI), consistently show that women taking combined estrogen-progestogen hormone replacement therapy have a significantly reduced risk of developing colorectal cancer — with some analyses suggesting a risk reduction in the range of 30 to 40 percent compared with non-users. The effect appears to be dose- and duration-dependent, with longer use associated with greater protection. This is one of the more robust non-reproductive benefits attributed to HRT in the evidence base.
Estrogen-only HRT also shows protective signals — but the picture is less clear
Women who take estrogen without progestogen (typically those who have had a hysterectomy) also show some reduction in colorectal cancer risk in observational data, though the effect size is generally smaller and less consistent than with combined therapy. Some researchers hypothesise that progestogen may contribute independently to colon protection, or that the combination acts synergistically on colonic tissue. The evidence here is sufficient to note a probable benefit, but not strong enough to draw firm conclusions.
The WHI HRT-and-cancer finding had a complication that is still misunderstood
The WHI trial found that women on combined HRT who did develop colorectal cancer were diagnosed at a more advanced stage than women not taking HRT — a counterintuitive finding that alarmed many clinicians. The leading explanation is that HRT may mask or delay symptoms such as rectal bleeding, or may reduce the sensitivity of certain screening markers, not that it accelerates cancer progression. This underscores why women on HRT should not skip or delay colorectal screening under any impression that hormones have eliminated the risk entirely.
Visceral fat accumulation after menopause is an independent colon cancer risk factor
Estrogen helps determine where fat is stored in the body, favouring subcutaneous (under-skin) fat during reproductive years. After menopause, fat preferentially redistributes to the abdomen as visceral fat, which is metabolically active and produces inflammatory cytokines and excess insulin — both of which are independently associated with increased colorectal cancer risk. This means the body shape changes many women notice during perimenopause are not just cosmetic; they carry a genuine oncological signal.
Lifestyle factors that help manage menopause symptoms also reduce colon cancer risk — and the overlap is significant
Regular physical activity, a fibre-rich diet, limited alcohol intake, and not smoking are consistently associated with lower colorectal cancer incidence in large population studies — and these same factors also improve menopause symptom burden, cardiovascular health, and bone density. A woman who builds these habits during perimenopause is therefore banking protective benefits across multiple systems simultaneously. This is not a coincidence of categories; the underlying mechanisms — reduced inflammation, better insulin sensitivity, healthier gut microbiome — are shared.
A personal or family history of gynaecological cancers can also signal elevated colorectal risk — and vice versa
Lynch syndrome, the most common hereditary colorectal cancer condition, is also associated with significantly elevated risk of endometrial, ovarian, and other gynaecological cancers — meaning a woman with a family history of these cancers may already be at higher baseline colorectal risk without knowing it. Conversely, a personal history of ovarian or endometrial cancer should prompt a conversation with a gastroenterologist about whether earlier or more frequent colonoscopy is warranted. The gynaecological and colorectal systems share enough genetic risk pathways that treating them in complete clinical isolation is a missed opportunity.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.